Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Alkylating
  • Dacarbazine
  • Lung Neoplasms
  • Small Cell Lung Carcinoma

abstract

  • Temozolomide 200 mg/m2/day for 5 days in 28-day cycles is tolerable and active in patients with relapsed SCLCs. No treatment-limiting prolonged cytopenias were observed, making this our preferred schedule for further studies. Acquisition of archived biospecimens is feasible and necessary in order to continue evaluating the role of MGMT as a predictive biomarker in SCLCs.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4497567

Digital Object Identifier (DOI)

  • 10.1016/j.lungcan.2014.08.007

PubMed ID

  • 25194640

Additional Document Info

start page

  • 237

end page

  • 40

volume

  • 86

number

  • 2